JNJ-28312141|cas 885692-52-4|DC Chemicals|Price|Buy

Cas No.:	885692-52-4
Chemical Name:	4-cyano-N-(5-(1-(2-(dimethylamino)acetyl)piperidin-4-yl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-2-yl)-1H-imidazole-2-carboxamide
Synonyms:	JNJ-28312141; JNJ28312141; JNJ 28312141.
SMILES:	O=C(C1=NC(C#N)=CN1)NC2=C(C3=CCCCC3)C=C(C4CCN(C(CN(C)C)=O)CC4)C=C2
Formula:	C₂₆H₃₂N₆O₂
M.Wt:	460.57
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

JNJ-28312141 is an orally active CSF1R inhibitor (Colony-stimulating factor-1 receptor, CRF1R) and also a FLT3 inhibitor. CSF1R is expressed by many tumors and is a growth factor For macrophages and mediates osteoclast differentiation. JNJ-28312141 represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events. For the detailed information of JNJ-28312141, the solubility of JNJ-28312141 in water, the solubility of JNJ-28312141 in DMSO, the solubility of JNJ-28312141 in PBS buffer, the animal experiment (test) of JNJ-28312141, the cell expriment (test) of JNJ-28312141, the in vivo, in vitro and clinical trial test of JNJ-28312141, the EC50, IC50,and Affinity of JNJ-28312141, Please contact DC Chemicals.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101

Cat. No.	Product name	Field of application
DC72526	BPR1R024 mesylate	BPR1R024 mesylate is an orally active and selective colony-stimulating factor-1 receptor (CSF1R) inhibitor. BPR1R024 has potent CSF1R inhibition activity with an IC50 value of 0.53 nM. BPR1R024 can be used for the research of immuno-oncology.
DC47703	BPR1R024	BPR1R024 is an orally active and selective CSF1R inhibitor with IC50 of 0.53 nM. BPR1R024 specifically inhibits protumor M2-like macrophage survival with a minimal effect on antitumor M1-like macrophage growth.
DC46183	TPX-0022(CSF1R-IN-2)	TPX-0022 (CSF1R-IN-2) is a potent inhibitor of MET/CSF1R/SRC with enzymatic kinase inhibition IC50s of 0.14 nM, 0.71 nM and 0.12 nM, respectively. TPX-0022 modulates the tumor immune microenvironment in preclinical models.
DC40860	DCC-3014(Vimseltinib)	DCC-3014(Vimseltinib) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of <0.01 μM and 0.1-1 μM, respectively.
DC8158	Pexidartinib(PLX3397)	PLX3397 is a tyrosine kinase inhibitor that potently inhibits the colony stimulating factor 1 (CSF1) receptor kinase, a driving force in the development and growth of PVNS.
DC7168	Ki20227	Ki-20227 is a highly selective c-Fms tyrosine kinase(CSF1R) inhibitor with IC50 value of 2 nM; 6 fold and > 100 fold selectivity over VEGFR2(IC50=12 nM) and c-Kit/PDGFR_beta_(IC50=451/217 nM), respectively.
DC7438	JNJ-28312141	JNJ-28312141 is an orally active CSF1R inhibitor (Colony-stimulating factor-1 receptor, CRF1R) and also a FLT3 inhibitor.
DC1018	GW-2580 (GW2580)	GW2580 is a selective inhibitor of human c-FMS with IC50 of 30 nM.
DC11398	Edicotinib（JNJ-40346527）	Edicotinib（JNJ-40346527）is a small molecule and orally available inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS) with potential antineoplastic activity.
DC8103	BLZ-945	BLZ945 is a highly selective and brain-penetrant inhibitor of CSF1R with IC50 of 1 nM; >3200-fold higher than its affinity for other kinases.